Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020191486 - ANTIGEN-BINDING AGENTS THAT SPECIFICALLY BIND EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III

Publication Number WO/2020/191486
Publication Date 01.10.2020
International Application No. PCT/CA2020/050378
International Filing Date 23.03.2020
IPC
C12N 15/62 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
A61K 35/12 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Applicants
  • NATIONAL RESEARCH COUNCIL OF CANADA [CA]/[CA]
Inventors
  • MCCOMB, Scott
  • WEERATNA, Risini Dhammika
  • JARAMILLO, Maria
  • MARCIL, Anne
  • SULEA, Traian
  • WU, Cunle
  • BLOEMBERG, Darin
Agents
  • BIOIPI INC.
Priority Data
62/824,39127.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIGEN-BINDING AGENTS THAT SPECIFICALLY BIND EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III
(FR) AGENTS DE LIAISON À L'ANTIGÈNE SE LIANT SPÉCIFIQUEMENT À LA VARIANTE III DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE
Abstract
(EN)
The present disclosure relates to antigen-binding agents that specifically bind to epidermal growth factor receptor variant III (EGFRvIII). Antigen-binding agents of the present disclosure include antibodies and antigen-binding fragments thereof, chimeric antigen receptors (CARs) and bi-specific T-cell engagers (BiTE!), bispecific killer cell engagers (BiKEs) and trispecific killer cell engagers (TriKEs). Nucleic acid molecules and vectors expressing antibodies, antigen-binding fragments, CARs, BiTEs, BiKEs or TriKEs are also encompassed by the present disclosure. Immune cells engineered to express CARs, BiTEs, BiKEs or TriKEs may be used to specifically recognize and kill cells expressing EGFRvIII.
(FR)
La présente invention concerne des agents de liaison à l'antigène se liant spécifiquement à la variante III du récepteur du facteur de croissance épidermique (EGFRvIII). Les agents de liaison à l'antigène de la présente invention comprennent des anticorps et des fragments de liaison à l'antigène correspondants, des récepteurs d'antigène chimériques (CAR) et des dispositifs de mise en prise de Lymphocytes T Bi-spécifiques (BiTE), des dispositifs de mise en contact de cellules tueuses bispécifiques (BiKE) et des dispositifs de mise en prise de cellules tueuses naturelles (TriKE). L'invention concerne également des molécules d'acide nucléique et des vecteurs exprimant des anticorps, des fragments de liaison à l'antigène, des CAR, des BiTE!, des BiKE ou des TriKE. Des cellules immunitaires modifiées pour exprimer des CAR, des BiTE, des BiKE ou des TriKE peuvent être utilisées pour reconnaître et tuer spécifiquement des cellules exprimant EGFRvIII.
Latest bibliographic data on file with the International Bureau